Impact of sustained viral response post curative therapy of hepatitis C-related hepatocellular carcinoma: A systematic review and meta-analysis

Abstract

Antiviral therapy with interferon based therapies (IBT) has shown potential in improving survival in patients who have undergone resection or locoregional therapy for hepatitis C-associated hepatocellular carcinoma (HCV-HCC). However, this benefit has not been definitively ascribed to sustained viral response (SVR). Since IBT has been replaced with new directly acting agents (DAA) which are more efficacious in the treatment of HCV, we sought to better determine the prognostic impact of SVR in HCV-HCC. A systematic search of MEDLINE and Embase from inception through October 2015 was performed to identify studies that described the impact of presence of SVR in patients who underwent curative treatment of HCV-HCC. Summary hazard ratio (HR) with 95% confidence intervals (CI) was estimated for recurrence-free survival (RFS) and Overall Survival (OS) utilizing a random-effects model. After reviewing 858 abstracts, ten studies which included a total of 1794 patients were selected and data was extracted. Of these ten studies, the impact of SVR on RFS and OS was reported in eight and seven studies respectively. In a meta-analysis which included 1519 patients, SVR was associated with improved OS (HR 0.18; 95% CI 0.11- 0.29, I²= 2%). We also found that SVR was associated with better RFS in a meta-analysis (1241 patients; HR 0.50; 95% CI 0.40-0.63, I²= 0). In conclusion, SVR is associated with improved OS and RFS in patients with HCV who have undergone resection or locoregional therapy for HCC. Newer DAA therapies which offer increased tolerability and viral eradication should be considered as adjunctive therapy. This article is protected by copyright. All rights reserved.

from Cancer via ola Kala on Inoreader http://ift.tt/2geToyq
via IFTTT